Medial EarlySign strives to improve patient health outcomes by finding extraordinary clinical insights "hidden" within existing medical data via coupling clinical expertise with state-of-the-art machine learning-based artificial intelligence technologies. Our goal is to aid healthcare organizations in identifying patients at high risk for debilitating medical conditions.
Medial EarlySign creates unique algorithm-powered software tools that give health professionals robust risk predictors that enhance care management opportunities by helping identify patients with life-altering medical conditions as early as possible, sometimes even before they appear symptomatic. We empower medical professionals with actionable insights extracted from existing, routine medical data. Our technologies enable healthcare organizations to focus on outcomes-based care and provide them with opportunities to delay the onset or progression of patients’ life-altering illnesses.
We research, build and test our data-driven core AI, AlgoAnalyzer™, and AlgoMarker™ healthcare technologies in many of the most important clinical practice areas. These medical specialties include cancers, diabetes and diabetic complications, as well as a variety other illnesses.